Arthneeti
All Q4 FY25 results →
VL

Vimta Labs Ltd

Q4 FY25Healthcare Services

Vimta Labs Q4 FY25 earnings call: Revenue & Margins

Q4 FY25 earnings call: what management guided on revenue, margins and order book.

Price₹630
Market cap₹2.8K Cr
P/E34.1
Updated23 Aug 2026
Read5 min read

The short version

Vimta Labs aims to achieve an exit run rate of INR125 crore per quarter by the end of FY 2025-26, reflecting significant revenue growth. Vimta Labs targets reaching an INR125 crore revenue run rate by the end of FY '26 Q4, indicating strong growth momentum.

From Vimta Labs Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Vimta Labs aims to achieve an exit run rate of INR125 crore per quarter by the end of FY 2025-26, reflecting significant revenue growth.
  • The company expects to maintain at least the same growth rate achieved in FY 2024-25 (around 19.1% year-on-year revenue growth).
  • Growth will be primarily driven by pharmaceutical (70% of revenue) and food testing (20% of revenue) segments.
  • Expansion in biologics and peptide CDMO services is underway, providing new revenue streams by backward integration of existing services.
  • The company anticipates continued healthy demand in pharma services, especially exports (36% of revenue), with 60% exposure to the U.S. market.
  • Capex of around INR90 crore planned for FY 2025-26 will further support capacity expansions to sustain growth over the next 5-6 years.

2 more points from Vimta Labs Ltd's call on revenue

Pro opens every point from 15K+ earnings calls

Profitability & Margins

See what Vimta Labs Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Capex guidance for FY '26 is around INR90 crores, mainly targeting equipment investment to propel growth.
  • Separate INR25 crores investment planned for biologics/peptide CDMO segment, over and above the INR90 crores capex.
  • Biologics segment capex (~INR25 crores) expected to partly require borrowing INR30-50 crores; mostly funded through internal accruals.
  • Recent new life sciences facility in Hyderabad commercialized; 70% capitalized; additional capacity created by shifting existing units.
  • Upcoming installation and qualification of electronic testing chamber expected by Q4 or early next year.
  • Incremental capex aims to support ~5-6 years of growth, adding lab space, equipment, and manpower progressively.

2 more points from Vimta Labs Ltd's call on capex

Pro opens every point from 15K+ earnings calls

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

Guidance-ranked
1Health X Platform
Rev 1Mar 1
2Chandan Healthca
Rev 1Mar 3
3
Rev 2Mar 1
4
Rev 2Mar 2
5
Rev 2Mar 2
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Vimta Labs Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript does not provide specific details on the current or expected order book or pending orders of Vimta Labs Limited. However, the following insights related to business prospects and demand can be noted: - The company is seeing traction in clinical trial RFPs with successful completion of the first trial and plans to onboard more trials during the year. - There is healthy demand in the pharmaceutical services segment, especially for small and large molecule analytical services. - Expansion and capex plans indicate preparedness for future growth but are flexible based on demand. - The management emphasizes strong repeat customer rates (upwards of 90%), reflecting good order continuity.

2 more points from Vimta Labs Ltd's call on order book

Pro opens every point from 15K+ earnings calls

Vimta Labs Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹109 Cr, net profit ₹21 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Vimta Labs's management said in earlier quarters

Others in Healthcare Services this season

  • 3B Blackbio (Q4 FY25)

    UK subsidiary (TRUPCR Europe Limited) revenue FY 2024-25: GBP 1,287,580, a 94% increase over FY 2023-24 GBP 664,059. Key concall takeaways from 3B Blackbio DX…

  • Apollo Hospitals Enterprise Ltd (Q4 FY25)

    . Key concall takeaways from Apollo Hospitals Enterprise Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.

  • Shalby (Q4 FY25)

    Implant business is in high-growth mode: 4x growth in Indonesia, 35-40% growth in U.S., and 2.5x growth in India reported last year. Key concall takeaways from…

  • Suraksha Diagnostic Ltd (Q4 FY25)

    Volume of tests conducted has been growing at around 10% year-on-year between FY '24 and FY '25. Key concall takeaways from Suraksha Diagnostic Ltd's Q4 FY25…

Compare:vs Apollo Hospitals Enterprise Ltdvs Manipal Health Enterprises Ltdvs Max Healthcare Institute Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Vimta Labs Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Vimta Labs Ltd Q4 FY25 results?

Vimta Labs aims to achieve an exit run rate of INR125 crore per quarter by the end of FY 2025-26, reflecting significant revenue growth. Vimta Labs targets reaching an INR125 crore revenue run rate by the end of FY '26 Q4, indicating strong growth momentum.

What is Vimta Labs Ltd share price analysis?

Vimta Labs Ltd currently shows a neutral. The stock trades at a P/E of 34.1 with a market cap of ₹2,757 Cr. Investors should review the full earnings analysis for detailed insights.

Is Vimta Labs Ltd planning capital expenditure?

Capex guidance for FY '26 is around INR90 crores, mainly targeting equipment investment to propel growth.

Keep Vimta Labs Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.